dihydroartemisinin

Overview

Dihydroartemisinin (DHA, also known as artenimol) is a semisynthetic artemisinin derivative with established antimalarial activity and broad experimental interest in biomedical research. In recent studies, it has been investigated as a pleiotropic small molecule with potential anti-inflammatory, anti-resorptive, immunomodulatory, and anticancer effects. Its research use extends beyond direct pharmacology to include incorporation into drug-delivery systems and chemical conjugates designed to improve tissue targeting and therapeutic selectivity.

Biologically, DHA is being explored in contexts where modulation of cell death, inflammatory signaling, oxidative stress, and tissue remodeling may be beneficial. The recent literature provided here places DHA in studies of lupus nephritis, malignant pleural effusion, bone remodeling, and nanoparticle-based delivery systems. In these settings, DHA is treated as an active therapeutic agent or as a molecular component of a prodrug/conjugate strategy, including DHA-ceramide and DHA-loaded zeolitic imidazolate framework-8 (ZIF-8) nanoparticles.

Focus of Latest Publications

Recent publications have examined dihydroartemisinin in several disease contexts, with emphasis on formulation, target identification, and mechanistic action.

In a study on lupus nephritis, dihydroartemisinin was reported to show good therapeutic effects, and the work identified CARD6 as a therapeutic target of DHA using proteolysis targeting chimera technology. This suggests that the compound’s benefit in lupus nephritis may involve targeted protein degradation or pathway modulation rather than only nonspecific cytotoxicity. The study adds to the evidence that DHA can act as an immunoregulatory agent in inflammatory kidney disease.

In malignant pleural effusion research, dihydroartemisinin was loaded into zeolitic imidazolate framework-8 (ZIF-8) nanoparticles to create a chemo-immunotherapeutic strategy. The authors aimed to determine whether this delivery platform could improve anti-malignant pleural effusion activity through inhibition of OCT4/M-CSF signaling. The work was framed around pleural tumor biology using human-derived MPE cells and supports the idea that DHA can be repurposed as part of a nanomedicine approach for cancer-associated effusions.

Another cancer-focused study investigated DHA in lung cancer models using aspartate-modified liposomes and zeolitic imidazolate framework-8-based delivery. The publication context indicates that DHA had pleiotropic anti-lung cancer effects and that nanoparticle loading was used to enhance therapeutic performance. This aligns with the broader strategy of improving DHA bioavailability and tumor targeting while leveraging its pro-oxidant or stress-sensitizing effects in malignant cells.

Across these studies, DHA was also discussed in relation to oxidative stress and ferroptosis, which are relevant to tumor cell vulnerability. In the provided publication context on algae oil-based emulsion therapy, docosahexaenoic acid (DHA in the lipid sense) was mentioned as a factor that can enhance tumor susceptibility to oxidative stress and ferroptosis; although this is a different entity from dihydroartemisinin, the shared abbreviation underscores the importance of distinguishing the two in biomedical literature.

Overall, the recent research portrays dihydroartemisinin as a multifunctional experimental therapeutic with activity in lupus nephritis, malignant pleural effusion, and lung cancer models, often enhanced by nanotechnology-based delivery systems and mechanistic targeting of signaling pathways such as OCT4/M-CSF and CARD6-associated processes.

Key Publications

NEWApr A novel algae oil-based emulsion enhances chemotherapy outcome in human cancer models. (Prostaglandins, leukotrienes, and essential fatty acids, 2026, PMID 42235481): "Omega-3 fatty acids, particularly docosahexaenoic acid (DHA), exhibit both nutritional and bioactive properties, including anti-inflammatory effects and the ability to enhance tumor cell susceptibility to oxidative stress and ferroptosis."
Jun Daily supplementation with egg yolk lipids from two eggs alleviated cognitive impairment in 5 × FAD mice by restoring neuronal and synaptic function and regulating gut microbiota. (Food & function, 2026, PMID 42300178): "Eggs are recommended by dietary guidelines as an effective vehicle for DHA intake, yet direct evidence on the health effects and optimal dosage of egg yolk lipids against Alzheimer's disease (AD) remains limited."
Jun Lysosome-triggered nanotherapy packages osteoclast apoptotic bodies with pro-anabolic lipids to couple anti-resorption and bone formation. (Pharmacological research, 2026, PMID 42069319): "After cellular uptake, lysosomal acid ceramidase cleaves DHA-ceramide to release sphingosine (SPH) and DHA."
May Caspase Recruitment Domain 6 (CARD6) is the therapeutic target of dihydroartemisinin for lupus nephritis based on Proteolysis Targeting Chimera (PROTAC) technology. (British journal of pharmacology, 2026, PMID 42152790): "Dihydroartemisinin (DHA; artenimol) shows good therapeutic effects on LN."
May Ameliorative effect of docosahexaenoic acid-acylated astaxanthin ester on diabetic nephropathy: association with the trehalose/HSP90AA1 and colon-kidney axis. (Food & function, 2026, PMID 42149022): "Specifically, relative to the DHA + AST group, DHA-AST gavage achieved selective colonic DHA enrichment, more effectively ameliorated systemic glucose dyshomeostasis, renal dysfunction, and histopathological damage, and suppressed renal inflammation, oxidative stress and fibrosis."
May Dihydroartemisinin-Loaded ZIF-8 Nanoparticles Elicit Chemo-Immunotherapy against Malignant Pleural Effusion via Inhibition of OCT4/M-CSF Signaling Pathway. (Molecular pharmaceutics, 2026, PMID 42020944): "Herein, we sought to figure out whether dihydroartemisinin (DHA), whose pleiotropic antilung cancer effects have been elucidated by our team, loaded with zeolite imidazole framework-8 (ZIF-8) could serve as a novel anti-MPE chemo-immunotherapeutic strategy."